Tuberculosis Diagnostics Market (By Test Type: Radiographic Method, Diagnostic Laboratory Methods, Nucleic Acid Testing, Phage Assay, Detection of Latent Infection (Skin Test & IGRA), Cytokine Detection Assay, Detection of Drug Resistance (DST), Other Methods; By End-use: Diagnostic Laboratories Hospitals & Clinics Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Tuberculosis Diagnostics Market 

5.1. COVID-19 Landscape: Tuberculosis Diagnostics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Tuberculosis Diagnostics Market, By Test Type

8.1. Tuberculosis Diagnostics Market, by Test Type, 2023-2032

8.1.1. Radiographic Method

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Diagnostic Laboratory Methods

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Nucleic Acid Testing

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Phage Assay

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Detection of Latent Infection (Skin Test & IGRA)

8.1.5.1. Market Revenue and Forecast (2020-2032)

8.1.6. Cytokine Detection Assay

8.1.6.1. Market Revenue and Forecast (2020-2032)

8.1.7. Detection of Drug Resistance (DST)

8.1.7.1. Market Revenue and Forecast (2020-2032)

8.1.8. Other Methods

8.1.8.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Tuberculosis Diagnostics Market, By End-use

9.1. Tuberculosis Diagnostics Market, by End-use, 2023-2032

9.1.1. Diagnostic Laboratories

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Hospitals & Clinics

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Others

9.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Tuberculosis Diagnostics Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.1.2. Market Revenue and Forecast, by End-use (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.1.3.2. Market Revenue and Forecast, by End-use (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.1.4.2. Market Revenue and Forecast, by End-use (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.2.2. Market Revenue and Forecast, by End-use (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.2.3.2. Market Revenue and Forecast, by End-use (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.2.4.2. Market Revenue and Forecast, by End-use (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.2.5.2. Market Revenue and Forecast, by End-use (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.2.6.2. Market Revenue and Forecast, by End-use (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.3.2. Market Revenue and Forecast, by End-use (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.3.3.2. Market Revenue and Forecast, by End-use (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.3.4.2. Market Revenue and Forecast, by End-use (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.3.5.2. Market Revenue and Forecast, by End-use (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.3.6.2. Market Revenue and Forecast, by End-use (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.4.2. Market Revenue and Forecast, by End-use (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.4.3.2. Market Revenue and Forecast, by End-use (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.4.4.2. Market Revenue and Forecast, by End-use (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.4.5.2. Market Revenue and Forecast, by End-use (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.4.6.2. Market Revenue and Forecast, by End-use (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.5.2. Market Revenue and Forecast, by End-use (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.5.3.2. Market Revenue and Forecast, by End-use (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Test Type (2020-2032)

10.5.4.2. Market Revenue and Forecast, by End-use (2020-2032)

Chapter 11. Company Profiles

11.1. Abbott Laboratories

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Becton, Dickinson and Company

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. F. Hoffmann-La Roche AG

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Thermo Fisher Scientific Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. BioMérieux SA

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Hain Lifescience GmbH

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. QIAGEN GmbH

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Cepheid

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Hologic, Inc.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. BD

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample